NKTR - Nektar Therapeutics

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
20.00
-0.10 (-0.50%)
As of 10:51AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close20.10
Open20.13
Bid19.94 x 800
Ask19.96 x 1200
Day's Range19.81 - 20.30
52 Week Range16.56 - 62.70
Volume286,300
Avg. Volume2,673,593
Market Cap3.505B
Beta (3Y Monthly)3.07
PE Ratio (TTM)N/A
EPS (TTM)-2.43
Earnings DateNov 5, 2019 - Nov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.33
Trade prices are not sourced from all markets
  • GlobeNewswire

    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NetApp, SAExploration, Nektar Therapeutics, and Valaris and Encourages Investors to Contact the Firm

    Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of NetApp, Inc. (NTAP), SAExploration Holdings, Inc. (SAEX), Nektar Therapeutics, Inc. (NKTR), and Valaris Plc (VAL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

  • ACCESSWIRE

    NKTR, PS & BRFRF, BRFRY - Class Action Update - Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, NY / ACCESSWIRE / September 18, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.

  • GlobeNewswire

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

    Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Valaris” or the “Company”) (NASDAQ: NKTR).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct.

  • GlobeNewswire

    Kessler Topaz Meltzer & Check, LLP Reminds Nektar Therapeutics Investors of Important Deadline in Securities Fraud Class Action Lawsuit

    The law firm of Kessler Topaz Meltzer & Check, LLP reminds Nektar Therapeutics (NASDAQ:  NKTR) (“Nektar”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against Nektar on behalf of those who purchased or otherwise acquired Nektar securities between February 15, 2019 and August 8, 2019, inclusive (the “Class Period”). Important Deadline Reminder:  Investors who purchased Nektar securities during the Class Period may, no later than October 18, 2019, seek to be appointed as a lead plaintiff representative of the class. According to the complaint, Nektar is a biopharmaceutical company that develops medicines in areas of high unmet medical need, including therapies for cancer, autoimmune disease, and chronic pain.

  • GlobeNewswire

    INVESTOR DEADLINES: Bernstein Liebhard LLP Reminds Investors in NKTR and GVA of Filing Deadlines

    NEW YORK, Sept. 17, 2019 -- Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of NKTR and GVA. If you wish to serve as.

  • 7 Stocks the Insiders Are Buying on Sale
    InvestorPlace

    7 Stocks the Insiders Are Buying on Sale

    [Editor's Note: This article is updated each week with the latest insider moves.]There are many reasons why an insider of a company may sell their stock. They may need to raise money for things such as a home purchase and a divorce settlement. However, there is only one reason why there would be insider buying of a stock. They believe that they will profit because it is currently undervalued.Insiders are people who have access to confidential information about a company. There have been numerous cases over the years where insiders take advantage of this in order to profit. For example, suppose an insider knows that news is about to be released that will make the stock go higher. The insider could buy it from a shareholder who does not have access to the news.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOne of the rules that the SEC has established to protect investors from this type of illicit activity is to require the insiders to publicly disclose when they are buying or selling their stock. This will help to prevent unethical insiders from taking advantage of uninformed investors.When I am thinking about buying a stock, I always like to see what the insiders are doing. I especially like to see if they are buying after the stock has seen a dramatic drop in price. This could be a sign that the stock is a good value at current levels. * 10 Recession-Resistant Services Stocks to Buy Here are seven stocks that insiders have been buying after they made large moves lower. The Chemours Company (CC)The Chemours Company (NYSE:CC) sells performance chemicals in markets all over the world.The price of CC stock has dropped from $40 a share to current levels around $16 since just this past April. This is due to the fact that the company has missed earnings estimates and reduced its guidance. Because of this, many of the firms that follow it on a research basis have reduced their ratings.Mark Newman is a Senior Vice President and the Chief Operating Officer of Chemours. He must believe that the stock is a great value at these levels because he just made a significant personal investment. Maybe he is attracted to the 6.1% dividend that the stock is currently yielding.On Sept. 11 he paid an average price of $16.42 for 20,000 shares. This was an investment of almost $330,000. Flowtek Industries Inc. (FTK)Flowtek Industries Inc. (NYSE:FTK) provides chemistry and other services to companies in the oil and gas industry.FTK stock dropped by about 40% in early August when shareholders were disappointed with earnings results. Before the report, shares were trading around $2.80. When the results were released, the stock fell to $2.The loss for the quarter was 21 cents. In fiscal 2018, the company reported a loss of $1.21 a share. This was significantly worse than the loss of 44 cents a share that was reported in 2017. * 10 Big IPO Stocks From 2019 to Watch David Nierenberg is a Director of the company. He must think that the sellers have overreacted to this news because he just made a substantial investment of almost $650,000. Between Sept. 10 and Sept. 12 Nierenberg acquired about 270,000 shares of stock. Signet Jewelers LTD. (SIG)Signet Jewelers LTD. (NYSE:SIG) sells jewelry, watches and other products.Like many other retailers, Signet has faced some challenges. This has caused the price of the stock to lose more than half of its value between March and early September.After reaching a 10-year low, SIG stock rallied after it reported earnings that were better than estimates. It also raised its guidance.Two insiders of this company must think that things are turning around and that this rally will continue. They each just made large purchases of the stock. Virginia Drosos is the CEO of Signet. She just made an investment of over $50,000 when she paid $14.14 for 4,000 shares.Joan Hilson is the Chief Financial Officer. She made an even larger investment when she bought 7,500 shares at $14.56 a share. This was almost $110,000. That's not chump change. Aerie Pharmaceuticals, Inc. (AERI)Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) develops and sells therapies for the treatment of eye diseases.Over the past year, the price of AERI stock dropped by more than 60%. Last September, shares traded for over $60 a share. This September, shares traded below $20.Because of this, there has been a significant amount of insider buying. Richard Rubino is the Chief Financial Officer of Aerie. He just invested $100,000 when he paid $19.93 for 5,040 shares.Vicente Anido is the CEO of the company. He must also be bullish on the long-term prospects. He just made an investment of $500,000 when he recently bought 26,000 shares. * 7 Dow Titans Breaking Higher Wall Street is also bullish on the company; 10 firms follow it and 9 of them have buy ratings on it. The average target price is around $63. This is almost 3 times higher than where it is currently trading. Phunware, Inc. (PHUN)Phunware, Inc. (NASDAQ:PHUN) provides multiscreen-as-a-service cloud platforms for mobile devices.Over the past few months, the price of PHUN stock has dropped from around $4 a share to as low as $1.14 in mid-August. Since then, it has had an impressive recovery and has rallied to current levels around $1.73.There have been some positive developments for Phunware. In July, the company announced that is had been added to the Russel Microcap index. In addition, it also announced that it has partnered with L&T Technology Services to implement its platform on a corporate campus for an undisclosed Fortune 50 company.Randal Crowder is the Chief Operating Officer of Phunware. He must believe that the stock will continue to rally. He recently bought almost 40,000 shares on the open market. There has been buying by other insiders as well. Nektar Therapeutics (NKTR)Nektar Therapeutics (NASDAQ:NKTR) develops drugs for cancer, autoimmune disease and chronic pain.Over the past year, the price of NKTR stock has dropped from $80 per share to current levels around $20. This could be because the company has reported losses in each of the last four quarters. In the most recent quarter, the loss for Nektar was 63 cents a share.Stephen Dobersten is a Senior Vice President and Chief Scientific Officer of the company. He must believe that the stock is a good value at these levels. He just invested $260,000 of his personal funds when he paid $17.28 for 15,000 shares. * 7 Momentum Stocks to Buy On the Dip The Street believes that the stock is undervalued as well; 13 firms follow NKTR stock. The average rating is overweight and the average target price is $39.45. This is almost twice as high as where it is currently trading. Meredith Corporation (MDP)Meredith Corporation (NYSE:MDP) operates as a diversified media company.MDP stock dropped by almost 25% in early September when the company reported earnings that disappointed investors. Since then it has recovered somewhat.Thomas Harty is the President and CEO of the company. He must believe that the sellers overreacted when they knocked the stock down. He just paid $35.02 for 12,000 shares. This was a personal investment of more than $420,000.Five Wall Street research firms follow Meredith and they seem to like it as well. The average rating is overweight. The average target price is $48.80. This is about 10 dollars higher than where it is currently trading. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Real Estate Investments to Ride Out the Current Storm * 7 Marijuana Penny Stocks to Consider for Those Who Can Handle Risk * 7 Safe Dividend Stocks for Investors to Buy Right Now The post 7 Stocks the Insiders Are Buying on Sale appeared first on InvestorPlace.

  • GlobeNewswire

    INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Nektar failed to comply with commonly accepted good manufacturing processes.

  • ACCESSWIRE

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

    NEW YORK, NY / ACCESSWIRE / September 16, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Valaris” or the “Company”) (NASDAQ:NKTR). Such investors are advised ...

  • ACCESSWIRE

    NKTR, PS & BRFRF, BRFRY - Class Action Reminder - Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, NY / ACCESSWIRE / September 16, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.

  • ACCESSWIRE

    NKTR NOTICE, ROSEN, A TOP FIRM, Announces Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR

    NEW YORK, N.Y. / ACCESSWIRE / September 16, 2019 / Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar ...

  • ACCESSWIRE

    Zhang Investor Law Announces the Filing of a Securities Class Action Lawsuit Against Nektar Therapeutics- NKTR

    NEW YORK, NY / ACCESSWIRE / September 13, 2019 / Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Nektar Therapeutics (NASDAQ:NKTR) between ...

  • GlobeNewswire

    Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Burford Capital Limited (BRFRF, BRFRY) Class Action Reminder - Bronstein, Gewirtz & Grossman, LLC

    Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

  • ACCESSWIRE

    NKTR, PS & BRFRF, BRFRY - Class Action - Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, NY / ACCESSWIRE / September 13, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.

  • GlobeNewswire

    ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Nektar Therapeutics Investors of Important October 18th Deadline in Securities Class Action - NKTR

    NEW YORK, Sept. 12, 2019 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nektar Therapeutics (NASDAQ: NKTR) from February 15, 2019.

  • NKTR CLASS ACTION ALERT: Bernstein Liebhard LLP Announces the Filing of a Securities Class Action Lawsuit Against Nektar Therapeutics
    PR Newswire

    NKTR CLASS ACTION ALERT: Bernstein Liebhard LLP Announces the Filing of a Securities Class Action Lawsuit Against Nektar Therapeutics

    NEW YORK, Sept. 12, 2019 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action has been filed on behalf of investors that purchased or acquired the securities of  Nektar Therapeutics ("Nektar" or the "Company") (NKTR) between February 15, 2019 and August 8, 2019, inclusive (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934. If you purchased Nektar securities, and/or would like to discuss your legal rights and options please visit Nektar Shareholder Class Action or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.

  • GlobeNewswire

    Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Nektar Therapeutics Investors

    Important Deadline Reminder:  Investors who purchased Nektar securities during the Class Period may, no later than October 18, 2019, seek to be appointed as a lead plaintiff representative of the class. According to the complaint, Nektar is a biopharmaceutical company that develops medicines in areas of high unmet medical need, including therapies for cancer, autoimmune disease, and chronic pain. In the PIVOT-02 clinical study, Nektar evaluates the benefit, safety, and tolerability of combining NKTR-214 with Opdivo, an antibody, in collaboration with Bristol-Meyers Squibb Company.

  • GlobeNewswire

    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nektar Therapeutics, Valaris, Burford, and Canada Goose and Encourages Investors to Contact the Firm

    Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Nektar Therapeutics (NKTR), Valaris Plc (VAL), Burford Capital Limited (Other OTC: BRFRF), and Canada Goose Holdings, Inc. (GOOS). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

  • GuruFocus.com

    Wall Street Posts Losses on Tuesday

    Casey's General Stores gains on financial results Continue reading...

  • GlobeNewswire

    INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Nektar failed to comply with commonly accepted good manufacturing processes.

  • ACCESSWIRE

    NKTR DEADLINE ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR

    NEW YORK, NY / ACCESSWIRE / September 10, 2019 / Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Nektar Therapeutics (NASDAQ:NKTR) ...

  • Why Is Nektar (NKTR) Down 42.5% Since Last Earnings Report?
    Zacks

    Why Is Nektar (NKTR) Down 42.5% Since Last Earnings Report?

    Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.